Ingalls & Snyder’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$687K Buy
75,450
+7,000
+10% +$49.8K 0.02% 255
2026
Q2
$452K Sell
68,450
-7,200
-10% -$49.6K 0.01% 319
2026
Q1
$548K Sell
75,650
-1,750
-2% -$14.1K 0.02% 279
2025
Q4
$584K Buy
77,400
+18,300
+31% +$113K 0.02% 274
2025
Q3
$349K Buy
59,100
+21,900
+59% +$119K 0.01% 353
2025
Q2
$214K Buy
+37,200
New +$143K 0.01% 418

Other funds holding EPRX

Ingalls & Snyder's EPRX Position: Q3 2026 in Review

Ingalls & Snyder increased its Eupraxia Pharmaceuticals (EPRX) stake by 10% in Q3 2026, buying an estimated $49.8K and bringing the position to 75,450 shares worth $687K. The position accounts for 0.02% of the portfolio, ranked #255.

Ingalls & Snyder first reported a position in EPRX in Q2 2025 and has held it in 6 quarters since. 70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

  • Ingalls & Snyder held 75,450 shares of Eupraxia Pharmaceuticals worth $687K as of Q3 2026.
  • Ingalls & Snyder bought 7,000 Eupraxia Pharmaceuticals shares in Q3 2026, an estimated $49.8K.
  • Eupraxia Pharmaceuticals made up 0.02% of Ingalls & Snyder's portfolio in Q3 2026, its #255 holding.
  • Ingalls & Snyder first reported a position in Eupraxia Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on Ingalls & Snyder's 13F filing for Q3 2026, filed 12 Nov 2026.